Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

If immunotherapy isn’t working, you might be missing the full picture #shorts

8 Mar 2026 · 1 min

Watch on YouTube

0:34

In this short video, Dino Prato, NMD highlights that a large majority (80–85%) of tumors classified as low immunotherapy‑responsive are actually considered untreatable with immunotherapy. He cites a Frontiers in Oncology study showing that PD‑1 inhibitors provide long‑term benefit to only about 19% of patients. Prato stresses that effective precision oncology requires comprehensive tumor marker profiling, warning that many patients mistakenly believe a limited genetic test (e.g., KRAS mutation screening) is sufficient, when it only offers a narrow view of the tumor’s biology.

Chapters

About 80 to 85% of the cases that are classified as low immunotherapy responsive tumors are considered not treatable with immunotherapy. Even if you had a PD-1 inhibitor that was approved for you as an immunotherapy, you're going to see that it only works long-term for about 19% of the patients according to Frontiers in Oncology. To deliver the right powerful treatment, you need all the markers. A lot of patients think they've already done genetic testing with a few of these DNA markers that looks for, let's say, a KRAS mutation. This is standard of care thinking, but in precision oncology, that is just telling us a little information of the tumor that we need to work around.